Spherix Global Insights

June 02, 2022

Biogen, Samsung Bioepis Launch First US Biosimilar, a Copycat of Roche’s Lucentis, at 40% Discount

Despite the partners’ excitement, a recent survey by Piper Sandler and Spherix Global Insights found that in the presence of Regeneron’s market-leading anti-VEGF eye drug, Eylea, ophthalmologists are “largely ambivalent” with Byooviz and other VEGF copycats of Roche’s Avastin.